Showing 241-250 of 355 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system | The University of North Carolina at Chapel Hill | Koji Sode | Improving Lives | 01-October-2022 to 30-September-2026 | $799,999.96 |
| GABP regulation of human beta cell proliferation | The University of Texas Health Science Center at Houston | Richard Cox | Cures | 01-September-2024 to 31-August-2027 | $200,000.00 |
| Enhancing Tidepool Loop for Unannounced Meals | Tidepool | Brandon Arbiter | Improving Lives | 01-June-2026 to 31-May-2029 | $2,175,732.12 |
| Development of Low Cost, High Precision Nano Pumps for Insulin Delivery | Torramics Inc. | Sergey Gimelshein | Improving Lives | 01-March-2023 to 30-April-2027 | $1,493,212.43 |
| Determining the role of SSTR2 on PRL-2903-mediated glucagon secretion | Trustees of Columbia University in the City of New York | Xiaojuan Chen | Improving Lives | 01-April-2026 to 31-March-2027 | $199,999.39 |
| Improving pig islet transplant efficacy in a preclinical baboon diabetes model with induced immune tolerance to the xenografts | Trustees of Columbia University in the City of New York | Megan Sykes | Cures | 01-June-2024 to 31-May-2027 | $791,063.66 |
| Preclinical optimization of Treg therapy to reverse autoimmunity in T1D patient-derived immune systems | Trustees of Columbia University in the City of New York | Megan Sykes | Cures | 01-August-2026 to 31-July-2029 | $1,189,893.00 |
| Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes | Trustees of Columbia University in the City of New York | Camillo Bechi Genzano | Cures | 01-March-2025 to 29-February-2028 | $253,647.64 |
| CGM-Derived Glucose Dynamic Index as Diagnostic Marker for Progression to Type 1 Diabetes | Trustees of Indiana University | Viral Shah | Cures | 01-November-2024 to 31-October-2027 | $900,000.00 |
| Safety and Efficacy of Adjunct Therapies in Adults with Type 1 diabetes: multicenter, registry-based study | Trustees of Indiana University | Viral Shah | Improving Lives | 01-September-2025 to 31-August-2028 | $1,603,777.39 |